Summary: New research identifies molecular signals that explain why some neurons are vulnerable to death in Alzheimer’s disease while neighboring neurons remain intact.
Source: Gladstone Institute
In Alzheimer’s disease, certain neurons progressively degenerate and die, causing the gradual loss of memory and cognitive abilities. Yet this degeneration is not uniform: some neuronal subtypes and even individual cells within the same subtype are more susceptible than others. Understanding what makes some neurons vulnerable and others resilient is key to developing targeted therapies for Alzheimer’s disease.
Researchers at Gladstone Institutes have identified molecular clues that help explain this selective vulnerability. Their study, published in Nature Neuroscience, links neuronal levels of apolipoprotein E (apoE) to immune-related gene activity inside neurons and to the likelihood that those neurons will degenerate.
Using advanced single-cell methods, the team shows that neurons with high apoE expression tend to activate major histocompatibility complex class I (MHC-I) genes and other immune-response pathways. This pattern is conserved across mouse models and human brain tissue and correlates with markers of Alzheimer’s pathology, including tau tangles and neuron loss.
“This is the first direct evidence connecting neuronal apoE levels with an intrinsic immune signature that may mark neurons for clearance,” says Gladstone Senior Investigator Yadong Huang, MD, PhD, who led the study. “These findings reveal a mechanism that could help explain selective neurodegeneration in Alzheimer’s disease and suggest potential points for therapeutic intervention.”
Comparing Individual Neurons with Single-Nucleus RNA Sequencing
ApoE has long been central to Alzheimer’s research because the apoE4 genetic variant increases disease risk. To study how apoE contributes to neuronal vulnerability, the researchers used single-nucleus RNA sequencing. This technique measures gene expression in individual nuclei, allowing a cell-by-cell view of which genes are active in each neuron.
The team analyzed brain tissue from healthy mice, mouse models of Alzheimer’s disease, and publicly available human datasets that included brains from people with and without Alzheimer’s pathology or mild cognitive impairment. Across species, they found wide variability in neuronal apoE expression—even among neurons of the same subtype—and a strong correlation between apoE levels and immune-response gene expression.
Specifically, neurons with elevated apoE also showed increased expression of MHC-I genes. MHC-I plays a role in trimming excess synaptic connections during development and can signal the immune system to recognize damaged cells. The link between apoE and MHC-I led the researchers to hypothesize that apoE may control an “eat me” signal that marks neurons for removal.
A Normally Protective Process That Can Become Harmful
Further experiments provided evidence of causality: altering neuronal apoE levels changed MHC-I expression, and those changes influenced tau pathology and neurodegeneration. Reducing MHC-I function in models with elevated apoE helped lessen tau-related damage. The data support a model in which apoE-driven MHC-I expression flags stressed or damaged neurons for elimination by immune mechanisms.
Under normal conditions, this clearance likely protects the brain by removing malfunctioning neurons. But in aging or under disease-related stressors, apoE levels in a larger proportion of neurons may rise, over-activating the MHC-I–linked pathway and causing excessive, selective neuron loss. Neurons expressing the apoE4 isoform appear particularly prone to this overactivation, which helps explain the heightened vulnerability associated with that genetic variant.
In contrast, neighboring neurons with lower apoE expression maintain lower MHC-I activity and tend to survive, producing the patchwork of degeneration and resilience observed in Alzheimer’s-affected brain regions. This pattern helps explain why some cells within the same neuronal class are lost while others persist.
These findings reveal a potential mechanism linking neuronal apoE expression to immune signaling, tau aggregation, and selective neurodegeneration in Alzheimer’s disease. By identifying how apoE upregulates MHC-I in neurons and how that drives tau pathology, the study suggests new avenues for therapeutic strategies aimed at interrupting this destructive cascade.
“Additional research will be needed to map precisely how apoE and MHC-I determine which neurons are removed and which survive,” says Kelly Zalocusky, PhD, first author of the study. “But targeting this pathway could offer ways to protect vulnerable neurons and slow disease progression.”
Other contributors to the study include researchers from Gladstone, UC San Francisco, and Rush University Medical Center. The work was supported in part by the U.S. National Institutes of Health (R01AG048017, RF1AG055421, and R01AG055682).
About this Alzheimer’s disease research news
Source: Gladstone Institutes
Contact: Julie Langelier – Gladstone Institutes
Image: The image is in the public domain
Original Research: Closed access. “Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer’s disease” by Kelly A. Zalocusky et al., Nature Neuroscience.
Abstract
Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer’s disease
Selective neurodegeneration is a key driver of Alzheimer’s disease, yet the molecular mechanisms explaining why some neurons die while others survive have been unclear. Using single-nucleus RNA sequencing, the authors found that variability in neuronal ApoE expression strongly correlates with activation of immune-response pathways, notably MHC-I, across wild-type mice, humanized ApoE mouse models, and human brain samples. Manipulating neuronal apoE levels altered MHC-I expression, tau pathology, and neurodegeneration, while reducing MHC-I function mitigated tau-related damage in models expressing apoE4. These results outline a pathway connecting neuronal ApoE to MHC-I induction, tau aggregation, and selective neuronal loss, offering potential targets for therapeutic intervention in Alzheimer’s disease.